InRetail Peru earnings date
InRetail Peru (INREF) Q3 2026 Earnings Report
INREF Q3 2026 EPS Results
- Actual EPS
- ―
- Consensus EPS
- ―
- Beat/Miss
- ―
- One Year Ago EPS
- $0.64
INREF Q3 2026 Revenue Results
- Actual Revenue
- ―
- Expected Revenue
- ―
- Beat/Miss
- ―
- YoY Revenue Growth
- ―
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/16/2026
- Time
- TBA
- Conference Call
- Monday, November 16, 2026
Q3 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was predominantly positive. InRetail reported strong revenue growth, resilient demand, solid segment performance, continued footprint expansion, improved leverage and raised revenue guidance. These positives were partly offset by lower net income, consolidated and Food Retail margin pressure, higher energy and logistics costs, a decline in Pharma distribution revenue and potential El Niño-related risks.
For full year 2026, InRetail raised its consolidated revenue guidance to low double-digit growth and reaffirmed its adjusted EBITDA guidance of low double-digit growth; by year-end, it expects to open now more than 100 Pharmacies across all formats, around 200 Hard Discount stores on a gross basis and one power center in the provinces, while Food Retail EBITDA margin should be relatively stable in 2027 and “remain relatively stable to what we end in 2026.” Sales in October and November were expected to remain similar, with double-digit growth in retail and Pharmacies “closer to high single digit, close to the 10%,” and management does not expect any additional provisions than the PEN 37 million already recorded by InFinance XP.
- Consolidated Revenue and EBITDA GrowthQ3 2026 consolidated revenue reached approximately PEN 6.3 billion, up 11.6% year-over-year, driven by double-digit growth in Food Retail and Shopping Malls. Adjusted EBITDA increased 8.8% to PEN 831 million.
- Raised Full-Year Revenue GuidanceThe company raised its full-year 2026 consolidated revenue guidance to low double-digit growth and maintained its adjusted EBITDA guidance of low double-digit growth.
- Resilient Domestic Demand and Multi-Format PlatformPeruvian domestic demand remained strong and overall consumption resilient. InRetail stated that its multi-format platform allowed it to capture this demand and strengthen its leadership across segments.
- Food Retail Revenue and Same-Store Sales GrowthFood Retail revenue grew 15.1% to PEN 3.6 billion, while same-store sales increased 11.6%, supported by double-digit growth in food and high single-digit growth in nonfood categories. Hard Discount and Cash & Carry same-store sales grew around 15%, and supermarkets grew 8.3%.
- Food Retail Store Expansion and Gross Margin ImprovementOver the last 12 months, Food Retail added 157 net new Hard Discount stores and 3 supermarkets, including 2 Plaza Vea stores in the provinces and the reopening of 1 Vivanda store in Lima. Gross margin expanded to 23.9% from 23.4%, while Cash & Carry and Hard Discount represented 52.1% of Food Retail revenue.
- Pharma Core Business GrowthPharma revenue increased 5.2% to PEN 2.4 billion, driven by 9.5% growth in the core Pharmacies unit, which represented 79% of segment revenue. Pharmacy same-store sales grew 7.1%, with resilient demand in pharmaceutical and non-pharmaceutical categories.
- Pharma EBITDA and Margin ExpansionPharma adjusted EBITDA increased 9.6% to PEN 440 million, and the segment margin expanded to 18.1% as higher gross margin more than offset incremental expenses from new stores and the ramp-up of the new distribution center.
- Pharma Store Network and Category ExpansionInRetail added 99 net new pharmacies over the last 12 months, including 56 Beauty & Personal Care locations through new openings and conversions. Remodeling supported growth in personal care, beauty, dermocosmetics, vitamins and supplements, while demand was particularly strong for antidiabetics and weight-loss medications, including GLP-1 therapies.
- Strong Shopping Malls PerformanceShopping Malls revenue increased 15.9% to PEN 217 million and adjusted EBITDA rose 16.2% to PEN 126 million. Revenue benefited from approximately 26,000 square meters of additional GLA, rent renewals, higher variable rent from stronger tenant sales and higher service income.
- High Mall Occupancy and Rental MarginShopping Malls occupancy remained high at 95.7%, and net rental margin expanded 89 basis points to 79.5%. The segment's last-twelve-month adjusted EBITDA surpassed its full-year 2024 level.
- Improved Leverage MetricsConsolidated net leverage declined to 1.8x from 2.0x in Q3 2025 and was stable quarter-over-quarter. InRetail Consumer reported net leverage of 1.4x, while Shopping Malls improved to 2.6x from 2.8x in Q2 2026 and 3.4x in Q3 2025.
- Cash Flow and LiquidityThe company generated PEN 1.5 billion of operating cash flow during the first nine months and ended the quarter with PEN 1.5 billion of cash. Excluding the PEN 100 million share buyback and PEN 65 million payment to complete the InFinance XP acquisition, cash would have been approximately PEN 2 billion, slightly above the year-end 2025 balance.
- Continued Growth InvestmentFirst-nine-month CapEx totaled PEN 578 million, with approximately 45% allocated to Food Retail, around 30% to Shopping Malls and the remainder to Pharma. Investments supported new store openings, land bank acquisitions, renovations, expansions, logistics and IT.
- Logistics and Store Renovation InitiativesThe company continued expanding its logistics capabilities and renovated more than 340 Hard Discount stores during the year, bringing the total stock of renovated stores to approximately 700. Management said same-store sales of around 15% reflected the contribution of stores renovated over the last couple of years.
- Planned Footprint ExpansionBy year-end, InRetail expects to open more than 100 pharmacies across all formats and around 200 Hard Discount stores on a gross basis, as well as one power center in the provinces that will include one supermarket. The company also advanced development of a new power center outside Lurín.
- Stable Recent Sales TrendsManagement stated that October and November sales trends were similar to those seen in the third quarter and second quarter, with double-digit retail growth and Pharmacy growth closer to high single digits, close to 10%.
- Energy Cost Mitigation and El Niño PreparationInRetail secured a long-term energy contract to mitigate electricity-cost volatility. The company is also preparing for El Niño through advance inventory purchases, including Pharma purchases in Q3 and planned Food Retail purchases in Q4 2026, while management stated that no logistics disruptions had occurred so far.
- No Expected Additional InFinance XP ProvisionInFinance XP recorded a PEN 37 million precautionary provision, of which 50% applies to InRetail. Management stated that, based on the information currently available and the latest El Niño outlook, it does not expect additional provisions beyond the PEN 37 million already recorded.
INREF Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Nov 16, 2026 | 2026 (Q3) | ―- | 0.64 | ― | |
| Aug 18, 2026 | 2026 (Q2) | ―0.71 | 0.57 | 24.08% (+0.14) | |
| May 07, 2026 | 2026 (Q1) | ―0.51 | 0.48 | 4.54% (+0.02) | |
| Feb 27, 2026 | 2025 (Q4) | ―0.93 | 0.73 | 27.40% (+0.20) | |
| Nov 13, 2025 | 2025 (Q3) | ―0.64 | 0.69 | -6.56% (-0.04) | |
| Aug 13, 2025 | 2025 (Q2) | ―0.57 | 0.45 | 26.77% (+0.12) | |
| May 13, 2025 | 2025 (Q1) | ―0.48 | 0.55 | -11.82% (-0.07) | |
| Feb 25, 2025 | 2024 (Q4) | ―0.73 | 0.8 | -8.18% (-0.07) | |
| Nov 12, 2024 | 2024 (Q3) | ―0.69 | 0.46 | 47.84% (+0.22) | |
| Aug 13, 2024 | 2024 (Q2) | ―0.45 | 0.56 | -19.72% (-0.11) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

